Gus Alva, MD, DFAPA, medical director of ATP Clinical Research, commented on the potential clinical impact of AXS-05 for agitation in Alzheimer disease, caregiver burden, and the evolving collaboration between neurology and psychiatry.
Gus Alva, MD, DFAPA
Advertisement
Articles by Gus Alva, MD, DFAPA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Former NFL Running Back Chris Johnson Diagnosed With ALS at 40
2
FDA Accepts Sarepta's sNDAs for Casimersen and Golodirsen for Duchenne Muscular Dystrophy
3
Long-Term Efficacy of Anti-CD20 Therapies in MS: What the Evidence Shows
4
FDA Aligns With Cognition Therapeutics on Phase 3 Trial Design for Zervimesine in DLB-Associated Psychosis
5